Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

AUTOIMMUNE DISEASE THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Others. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets.The report profiles 138 companies including many key and niche players such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck & Co., Inc, Merck Serono SA, Novartis AG, Sanofi-aventis SA , Shire Plc, Teva Pharmaceuticals Industries Limited, and UCB S.A. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1829
Price : $4500
Companies : 138
Pages : 938
Date : October 2011
Market Data Tables : 219
Status: * New Report

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  AUTOIMMUNE DISEASE THERAPEUTICS (Complete Report) Pages : 938   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......14 $295  
   Study Reliability and Reporting Limitations.......1  
   Disclaimers.......2  
   Data Interpretation & Reporting Level.......3
Quantitative Techniques & Analytics.......3
Product Definition and Scope of Study.......3
  
   Rheumatoid Arthritis.......4
Multiple Sclerosis.......4
Psoriasis.......4
Crohn's disease.......4
  
  2. INDUSTRY OVERVIEW & OUTLOOK.......54 $295  
   Autoimmune Disease Therapeutics Market Continues to Flourish.......5
Pharmaceutical Industry Hit by Economic Downturn.......5
1$100
   Economic Downturn Takes Toll on R&D.......6
Current and Future Analysis.......6
Segment Analysis.......6
1$100
   Rheumatoid Arthritis Therapeutics – The Largest Segment.......7
Multiple Sclerosis Therapeutics Market.......7
Crohn’s Disease Therapeutics Market.......7
1$100
   Ulcerative Colitis Drugs Market.......81$100
  3. MARKET DYNAMICS AND TRENDS.......93 $295  
   Biologics Find Acceptance as First Line of Treatment for Autoimmune Diseases.......9
High Unmet Need Favors Growth.......9
Impact of Biosimilars Legislation on Biologic Arthritis Drugs Market.......9
1$100
   New Products to Drive Market Growth.......10
Biogenerics to Expand Adoption of Biological Drugs.......10
1$100
   Risk of Cancer Due to Anti-TNF Drugs.......11
Superior Outcomes to Enhance Adoption of Biologics.......11
Efficacy and Convenience – Key Factors Driving Physician’s Decision.......11
1$100
  4. DISEASE OVERVIEW.......129 $950  
   Immunity and Immune System.......12
Autoimmune Diseases.......12
Women- Highly Susceptible to Autoimmune Diseases.......12
1$100
   Table 1: Percentage Breakdown of Incidence of Autoimmune Diseases in Men and Women (includes corresponding Graph/Chart).......131$350
   Complexity in Manifestations Renders Difficulty in Understanding the
  Conditions.......14
Etiology of Autoimmune Diseases.......14
Genetic Predisposition.......14
1$100
   Environmental Factors.......15
Autoimmune Diseases – A Social and Health Burden.......15
1$100
   Regulatory Glitches and High Costs Hinder Biogenerics.......16
Types of Autoimmune Diseases.......16
1$100
   Incidence and Prevalence.......17
Diagnosis and Treatment of Autoimmune Diseases.......17
Overview on Select Biologic Drugs.......17
Remicade.......17
1$100
   Humira.......18
Rituxan® (rituximab).......18
1$100
   Cimzia.......191$100
   Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market.......20
Psoriasis – A Promising Market for Cimzia.......20
Actemra.......20
Enbrel.......20
1$100
  5. OVERVIEW OF SELECT AUTOIMMUNE DISEASES.......2131 $1995  
   Rheumatoid Arthritis.......21
Disease Overview.......21
Low Penetration to Sustain growth of Anti-TNF Drugs.......21
Incidence and Prevalence Higher in Urban and Developed Regions.......21
1$100
   Symptoms and Diagnosis.......22
Treatment of Rheumatoid Arthritis.......22
BRMs Revolutionize RA Treatment.......22
1$100
   Branded Products.......23
Drugs Used in Treating Rheumatoid Arthritis.......23
Year of Approval of Leading Biologics in Rheumatoid Arthritis Therapy.......23
1$100
   Key Drugs in Late Stage Development for Rheumatoid Arthritis Treatment.......24
Competitive Landscape.......24
1$100
   Table 2: Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scores by End Point.......25
High Prices and Safety Concerns.......25
Multiple Sclerosis.......25
1$350
   Etiology.......26
Types of Multiple Sclerosis.......26
1$100
   Table 3: Prevalence of Different Types of Multiple Sclerosis.......27
Pathology.......27
Prevalence of Multiple Sclerosis High in Women.......27
Facts About Multiple Sclerosis.......27
1$350
   Treatment.......28
Interferon Drugs - High Efficacy Drugs in Existing MS Therapies.......28
1$100
   Beta Interferon Drugs in Multiple Sclerosis Treatment.......29
Non-Interferon Drugs.......29
Non-Interferon Drugs in Multiple Sclerosis Treatment.......29
1$100
   Trends in Multiple Sclerosis Market.......30
High Unmet Need and Rich Pipeline to Expand MS Market.......30
Interferon-based Drugs Lead Multiple Sclerosis Drug Market.......30
1$100
   Oral Drugs Alter Dynamics in MS Therapies Market.......31
Dip in Sales Inevitable for Current Therapies.......31
1$100
   Tough Times Ahead for Betaseron.......32
Competitive Landscape.......32
1$100
   Table 4: Leading Products/Companies in the Global Multiple Sclerosis Therapeutics Market (2010): Percentage Share Breakdown of Value Sales for Biogen Idec, Teva/sanofi-aventis*, Merck Serono, Bayer Schering, Elan, and Others (includes corresponding Graph/Chart).......331$350
   Multiple Sclerosis Drug Pipeline – An Overview.......34
Drugs Under Development for Treating Multiple Sclerosis.......34
Fingolimod (Gilenya).......34
Mylinax.......34
1$100
   Laquinimod.......35
Campath (Alemtuzumab).......35
1$100
   Teriflunomide.......36
Fampridine-SR.......36
BG-12 (Oral Fumarate).......36
1$100
   MN-166.......37
Psoriasis.......37
Prevalence.......37
1$100
   Available Treatment Options.......38
Biological Drugs.......38
1$100
   Biological Drugs Lead the Fray.......39
Potential Therapeutic Products.......39
1$100
   Inflammatory Bowel Diseases.......40
Crohn's disease.......40
Stages of the Disease.......40
Prevalence.......40
1$100
   Diagnosis.......41
Treatment.......41
1$100
   Ulcerative Colitis.......42
Diagnosis and Treatment.......42
1$100
   Other Diseases.......43
Systemic Lupus Erythematosus (SLE).......43
Prevalence and Epidemiology.......43
Treatment.......43
1$100
   Sjogren's Syndrome.......441$100
   Prevalence and Epidemiology.......45
Diagnosis and Treatment.......45
1$100
   Type-1 Diabetes Mellitus.......46
Types of Diabetes Mellitus.......46
Type 1 or Insulin Dependent Diabetes Mellitus.......46
Type 2 or Non-Insulin Dependent Diabetes Mellitus.......46
Insulin – Vital for Blood Glucose Management.......46
Etiology.......46
1$100
   Prevalence.......47
Diabetes in Children - A Growing Concern.......47
Diagnosis and Treatment.......47
1$100
   Autoimmune Hepatitis.......48
Disease Categories.......48
Treatment.......48
Side Effects.......48
1$100
   Juvenile Rheumatoid Arthritis.......49
Symptoms.......49
Diagnosis.......49
Scleroderma.......49
1$100
   Prevalence.......50
Etiology.......50
Diagnosis.......50
Management.......50
1$100
   Vasculitis Syndeomes.......51
Haematologic Autoimmune Diseases.......51
Ankylosing Spondylitis.......51
1$100
  6. CLINICAL TRIALS & RESEARCH STUDIES.......5213 $950  
   Antares Pharma Commences VIBEX MTX Clinical Trial for Treating Rheumatoid
  Arthritis.......52
Avila Therapeutics Introduces Btk Inhibitor for Treating Autoimmune Diseases and
  Cancer.......52
Athersys and Angiotech to Conduct MultiStem® Clinical Trial.......52
1$100
   BioMarin Commences Amifampridine Phosphate Clinical Trial for Treating LEMS.......53
TxCell Successfully Completes Trial for Crohn's Disease Cell Therapy.......53
Novartis Releases Phase II Data for AIN457.......53
1$100
   Sanofi Releases Phase III TEMSO Study Results of Teriflunomide.......54
Biogen Achieves Positive Results for BG-12 Drug Trial.......54
Innate Therapeutics Commences MIS416 Clinical Trial in Progressive MS Patients.......54
1$100
   Pfizer Completes Clinical Trials for Tasocitinib.......55
Compugen Completes Animal Model Study of CGEN-15001.......55
1$100
   Avila Therapeutics Commences AVL-292 Clinical Trial.......56
Horizon Pharma Completes Clinical Trials for LODOTRA®.......56
1$100
   ChemoCentryx Begins Phase 1 Clinical trial for CCX168.......57
NYU Langone Medical Center Announces Potential Therapy for Rheumatoid
  Arthritis.......57
Compugen to Start Preclinical Development for Therapeutic Drugs.......57
1$100
   Avila Therapeutics Begins Phase I Clinical Trial for AVL-292.......58
VBL Therapeutics Releases Preclinical Data for VB-201.......58
1$100
   GlaxoSmithKline and Dynavax Select DV1179 for Endosomal TLR Inhibitor Program.......591$100
   Idera Pharmaceuticals Starts Phase 1 Clinical Study of IMO-3100.......60
ChemoCentryx Begins Phase I Clinical Study of CCX168.......60
1$100
   VBL Therapeutics Starts Phase II Clinical Study of VB-201.......611$100
   ChemoCentryx Begins Phase II Clinical Study of CCX354.......62
Neovacs Starts Phase IIa Clinical Study of TNF Kinoid.......62
1$100
   Galapagos Begins Phase II Clinical Study of Nanocort.......63
Plexxikon Starts Dosing of PLX3397 in Phase I Clinical Study.......63
2$200
  7. PRODUCT INTRODUCTIONS/APPROVALS.......659 $595  
   Horizon Pharma Receives FDA Approval for DUEXIS®.......65
Venus Remedies to Launch Trois.......65
CNRS/Inserm Researchers Introduce Dendrimer ABP as RA Therapy.......65
1$100
   Food and Drug Monitoring Agency to Approve Tocilizumab for Commercial Use.......66
Novartis Bags EC Approval for Gilenya®.......66
Genentech Obtains FDA Approval for ACTEMRA.......66
Novartis Gains Approval for Gilenya in Japan.......66
1$100
   Novartis Receives FDA Approval for Gilenya.......67
Compugen Discovers and Validates CGEN-15001 Soluble Recombinant Fusion Protein.......67
InNexus Biotechnology Develops IXSCD11a.......67
1$100
   Centocor Ortho Biotech Submits sBLA for Simponi Label Extension.......68
Osiris Therapeutics Obtains Orphan Drug Designation for Prochymal from FDA.......68
Immunomedics Obtains US Patent for Immunotherapy.......68
1$100
   Biogen Idec Introduces Monoclonal Antibody Tysabri in India.......69
Merck Serono Unveils Pre-Filled Pen RebiDose™ in UK.......69
BioMarin Unveils Firdapse™ in European Union.......69
1$100
   Sandoz Introduces Calcipotriene Solution in US.......70
Cimzia® Receives FDA Approval for Treating Rheumatoid Arthritis.......70
Simponi™ Receives FDA Approval for Treating Rheumatoid Arthritis.......70
Novartis Introduces Extavia® for Multiple Sclerosis Treatment in Denmark &
  Germany.......70
1$100
   Novartis Bags FDA Approval for Extavia.......71
UCB Receives EC Approval for Cimzia.......71
Centocor Ortho Biotech Receives FDA Approval for Stelara.......71
BioMarin Pharmaceutical Bags FDA’s Orphan Drug Designation.......71
Promius Pharma Introduces Scytera™ for Psoriasis Treatment.......71
1$100
   Galderma Receives FDA Approval for Plaque Psoriasis Ointment Vectical™.......72
Roche Obtains EC Approval for Rheumatoid Arthritis Antibody RoACTEMRA.......72
Viron Therapeutics Obtains US Patents for VT-384, VT-346 Candidates.......72
Bayer Schering Pharma Obtains Approval for Betafron® Therapy from SFDA.......72
1$100
   US Food and Drug Administration Approves Certolizumab Pegol.......73
Nitec Unveils Lodotra® in Germany.......73
1$100
  8. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST – A PERSPECTIVE
  BUILDER.......74
5 $395  
   HUMIRA® Obtains EU Approval for Polyarticular Juvenile Idiopathic Arthritis.......74
Cimzia® Receives FDA Nod for Treating Crohn’s Disease.......74
HUMIRA® Obtains Approval from Japanese Ministry for Rheumatoid Arthritis.......74
HUMIRA® Receives FDA Clerance for Polyarticular Juvenile Idiopathic Arthritis.......74
1$100
   Abbott Receives EU Marketing Authorization for Humira in Psoriasis Treatment.......75
Xian-Janssen Introduces Remicade, Branded infliximab in China.......75
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease.......75
HUMIRA® Obtains FDA Approval for Crohn’s Disease.......75
1$100
   Remicade® Obtains Approval for Use in PsA and Early RA in Australia.......76
Tysabri™ Receives Health Canada Approval for Use in Multiple Sclerosis.......76
Rituxan® Gets FDA Approval for Use in RA.......76
1$100
   Humira® Obtains FDA Approval for Treating AS.......77
Betaseron® Receives FDA Approval for Use in First Clinical Episode of MS.......77
1$100
   Abbott Receives FDA Clearance for HUMIRA Pen.......78
Remicade Obtains FDA Approval for Treating Pediatric Crohn`s Disease.......78
1$100
  9. RECENT INDUSTRY ACTIVITY.......7921 $1450  
   Sanofi-Aventis Takes over Genzyme.......79
Daiichi Sankyo to Acquire Plexxikon.......79
TiGenix Takes Over Cellerix.......79
Alkermes and Elan Drug Technologies to Merge Operations.......79
1$100
   Pfizer Japan Inks Agreements with Takeda to Co-Promote RA Drugs.......80
Viropro Inks Letter of Agreement with Spectrum Pharmaceuticals.......80
1$100
   Pepscan Therapeutics Collaborates with Phylogica.......81
Lycera Enters into Research Collaboration with Merck.......81
Merck Amends Distribution Agreement with Johnson & Johnson.......81
Yale University and Debiopharm Enter into License Agreement for Debio 1036.......81
1$100
   Opexa Therapeutics Inks Agreement with American Red Cross.......82
Antitope and NasVax Enter into Research Collaboration.......82
SuppreMol Inks In-License Agreement with Bayerische Patentallianz.......82
1$100
   Glenmark Inks License Agreement with Sanofi.......83
Exagen Enters into Partnership with Medco.......83
1$100
   Phylogica Inks Research Collaboration and Option Agreement with Pepscan
  Therapeutics.......84
Merck Sharp & Dohme Enters into Partnership with Lycera.......84
Amgen Enters into Collaboration with Xencor.......84
1$100
   PhRMA Announces Development of Medicines Targeted Towards Women.......85
Circassia Secures Global Development and Marketing Rights to PAP-1 from Airmid.......85
UCB Establishes Microbial Production Facility.......85
Emergent BioSolutions Takes Over Trubion Pharmaceuticals.......85
1$100
   Gilead Sciences to Takeover CGI Pharmaceuticals.......86
Abbott Laboratories Acquires Facet Biotech.......86
1$100
   Merck Takes Over Millipore.......87
Quidel to Snap Up Diagnostic Hybrids.......87
Nitec Pharma Merges with Horizon Therapeutics.......87
Femta Pharmaceuticals Inks Manufacturing Agreement with Lonza Group.......87
1$100
   Horizon Pharma Signs Agreement with Mundipharma International.......88
3SBio Signs Agreement with Isotechnika Pharma.......88
1$100
   Fast Forward and Provid Pharmaceuticals Extend Partnership.......89
Antitope and PIKAMAB Collaborate.......89
Ligon Discovery Enters into Agreement with Lycera.......89
Axxam, Fast Forward and Juvenile Diabetes Research Foundation Enter into
  Partnership.......89
1$100
   GlaxoSmithKline Collaborates with ChemoCentryx.......90
Perseid Signs Agreement with Astellas Pharma for CTLA4-Ig Program.......90
Cellceutix Chooses Destum Partners for KM-133 Psoriasis Compound.......90
1$100
   NERC Commences Operations of IXO Therapeutics.......91
Avesthagen to Market Avent.......91
Isotechnika Pharma Divests Stake in Isodiagnostika.......91
1$100
   MacroGenics Obtains New Grants from NIH.......92
AnaptysBio Collaborates with VLST to Generate Novel Antibody Therapeutics.......92
AstraZeneca Enters into Exclusive License Agreement with Rigel Pharmaceuticals.......92
Immutep Inks License Agreement with GlaxoSmithKline for Therapeutic Antibody
  IMP731.......92
1$100
   Novo Nordisk Inks Research Collaboration Agreement with Combine.......93
Xention and Axxam Enter into Autoimmune Disorder Research Partnership.......93
Roche Takes Over Genentech.......93
1$100
   Merck Acquires Schering-Plough.......94
Pfizer Takes Over Wyeth.......94
Amgen Takes Over Immunex.......94
BioMarin Pharmaceutical Takes Over Huxley Pharmaceuticals.......94
1$100
   Onyx to Takeover Proteolix.......95
Genzyme Takes Over Global Rights of Campath, Leukine and Fludara from Bayer.......95
Bristol-Myers Squibb Enters into Agreement with Alder Biopharmaceuticals.......95
LEO Pharma Inks Agreement with Warner Chilcott.......95
1$100
   Kineta One Acquires Commercial Rights for Compounds from Airmid.......96
Kineta Signs Agreement with Alturas Analytics.......96
Catalyst Biosciences in Research and License Agreement with MedImmune.......96
1$100
   Boehringer Ingelheimes Collaborates with Exelixis.......97
Lonza Signs Agreement with Opsona Therapeutics for Manufacturing Antibody.......97
Eli Lilly and Incyte Enter into Agreement.......97
Novartis Option Fund and Avila Therapeutics Sign Option Agreement.......97
1$100
   Genentech Acquires Rights for BHT-3021 from Bayhill Therapeutics.......98
Celentyx and Meiji Seika Kaisha Ink Agreement.......98
Exelixis and Boehringer Ingelheim Enter into Autoimmune Disease Partnership.......98
Celldex Acquires Exclusive Rights of Immune-Stimulatory Molecules from Amgen.......98
1$100
   Apitope and Merck Serono Sign Agreement for Multiple Sclerosis Drug.......99
Biovitrum and Affibody® Enter into Collaboration.......99
Bayhill Therapeutics Bags Contract from Genentech.......99
1$100
  10. CORPORATE ACTIVITY IN THE RECENT PAST – A PERSPECTIVE BUILDER.......10027 $2450  
   Novo Nordisk and VLST Collaborate on Therapeutic Targets Development.......100
Actemra’s Approval Gets Delayed.......100
1$100
   Apitope Raises Financing for Developing Multiple Sclerosis Compound.......101
CalciMedica to Acquire Rights to STIM1 from TorreyPines.......101
1$100
   Roche Acquires ARIUS Research, Inc........102
Astellas Inks Agreement with Maxygen for MAXY-4 Candidates.......102
1$100
   Carna and Caliper Life Sciences Ink Collaborative Supply Agreement.......1031$100
   Isotechnika Gets Back Worldwide Rights to Transplant Drug, Voclosporin.......104
Boehringer In-licenses Two Drug Targets from BioFocus.......104
Bionomics Enters into a Development and Licensing Agreement with Merck Serono.......104
1$100
   Nycomed Inks Agreement with Immunomedics for Veltuzumab.......105
EpiVax Receives Grants from National Institutes of Health to Advance Epi-13.......105
1$100
   Boehringer to Takeover Actimis.......106
Antisoma Acquires Xanthus Pharmaceuticals.......106
1$100
   Merrimack Acquires Funds for Developing Cancer and Autoimmune Disease
  Biologics.......107
BioSeek and Merck Sign Collaboration Agreement for Compound Evaluation.......107
Questcor Amends Distribution Contract with US Distributor of Acthar.......107
1$100
   ANP Completes Phase IIa Trial for Multiple Sclerosis Drug.......108
Insert and Calando Merge to Form Calando Pharmaceuticals.......108
Codon Inks Research & Development and Licensing Deal with Merrimack.......108
1$100
   Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK Peptide.......109
Chelsea Acquires Global Rights to I-3D Range of DHODH Inhibiting Compounds.......109
1$100
   Cypress Bioscience Acquires Proprius.......110
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals.......110
GlaxoSmithKline Acquires License to Market Vaccinex’s Antibody.......110
1$100
   Teva to Takeover CoGenesys.......111
Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune Diseases.......111
Anthera Acquires Rights to Develop and Market AMG 623 from Amgen.......111
Can-Fite Enters into Two Cooperation Agreements to Develop CF102 Drug.......111
1$100
   Source MDx Inks an Agreement with Pfizer.......112
Cambridge Inks an Antibody Development Agreement with Medarex.......112
Pfizer to Acquire Coley Pharma.......112
1$100
   GSK Joins Hands with Tolerx to Develop and Commercialize otelixizumab.......1131$100
   Amgen Acquires Avidia.......114
Eli Lilly and MacroGenics Tie Up for Developing Teplizumab.......114
1$100
   MorphoSys and Genesis Ink Antibody R&D Deal.......115
arGentis Enters into a License Agreement with UTRF.......115
Eden Biodesign to Investigate Novel Drug Candidate for Autoimmune Diseases.......115
1$100
   Nuon and Kissei Team up for Tranilast.......116
Organon and Dyax Team Up for Developing Therapeutic Antibodies.......116
Medarex Joins Hands with Mitsubishi for Monoclonal Antibody Development.......116
Merck and Archemix Collaborate.......116
1$100
   Genzyme Takes Over Bioenvision.......117
Organon and Medarex Ink Drug Development Deal.......117
CalciMedica Secures Exclusive Rights for CBR’s Autoimmune Drug Target.......117
1$100
   Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway.......118
Eisai Corporation Acquires Morphotek.......118
1$100
   TIRC Changes Name to Orchestra Therapeutics.......119
Abbott Files HUMIRA® for Psoriasis in the US and EU (USA/Europe).......119
1$100
   Accentia Secures Exclusive Global Rights to Revimmune.......120
Medarex and Compugen Ink Collaborative Agreement for Therapeutic Antibody.......120
1$100
   SRI and Telik Sign License Agreement for Drug Development.......1211$100
   China Biopharma Signs Agreement with Chinese Biopharmaceutical Firm.......122
Kirin and Astellas Ink Licensing Agreement for Anti-CD40 Antagonistic mAb.......122
1$100
   QSV and Artielle Sign Contract to Produce RTL-1000.......123
JDRF and MacroGenics Form Partnership.......123
1$100
   GSK and Genmad Sign Partnership Agreement for HuMaxCD20.......124
Biocon Enters into Joint Venture Agreement with Neopharma.......124
1$100
   Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals.......125
Astellas Acquires Worldwide Rights for Amevive®.......125
Biogen Acquires Fumapharm.......125
1$100
   Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy.......1261$100
  11. FOCUS ON SELECT GLOBAL PLAYERS.......12714 $950  
   Abbott Laboratories (USA).......127
Amgen Inc. (USA).......127
1$100
   Bayer Schering Pharma AG (Germany).......1281$100
   Biogen Idec Inc. (USA).......1291$100
   Bristol-Myers Squibb Company (USA).......130
Elan Corporation plc (Ireland).......130
1$100
   Eli Lilly and Company (USA).......1311$100
   F. Hoffmann-La Roche AG (Switzerland).......1321$100
   Chugai Pharmaceutical Co., Ltd. (Japan).......1331$100
   Genentech, Inc. (USA).......1341$100
   GlaxoSmithKline Plc (UK).......1351$100
   Johnson & Johnson, Inc. (USA).......136
Merck & Co., Inc. (US).......136
1$100
   Merck Serono SA (Switzerland).......137
Novartis AG (Switzerland).......137
1$100
   Sanofi-aventis SA (France).......1381$100
   Shire Plc (Ireland).......139
Teva Pharmaceuticals Industries Limited (Israel).......139
1$100
   UCB S.A. (Belgium).......1401$100
  12. GLOBAL MARKET PERSPECTIVE.......141   
   Table 5: World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......1411$350
   Table 6: World Historic Review for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......1421$350
   Table 7: World 15-year Perspective for Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1431$350
   Table 8: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......1441$350
   Table 9: World Historic Review for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......1451$350
   Table 10: World 15-year Perspective for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1461$350
   Table 11: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......1471$350
   Table 12: World Historic Review for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......1481$350
   Table 13: World 15-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1491$350
   Table 14: World Recent Past, Current & Future Analysis for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......1501$350
   Table 15: World Historic Review for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......1511$350
   Table 16: World 15-year Perspective for Psoriasis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1521$350
   Table 17: World Recent Past, Current & Future Analysis for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......1531$350
   Table 18: World Historic Review for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......1541$350
   Table 19: World 15-year Perspective for Crohn’s Disease Therapeutics (Biologicals) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1551$350
   Table 20: World Recent Past, Current & Future Analysis for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......1561$350
   Table 21: World Historic Review for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......1571$350
   Table 22: World 15-year Perspective for Other Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......1581$350
  13. THE UNITED STATES.......15953 $3950  
   A. Market Analysis.......159
Current and Future Analysis.......159
Autoimmune Diseases Fact Sheet.......159
1$100
   Table 23: Prevalence of Key Autoimmune Diseases in the US (in Millions) (includes corresponding Graph/Chart).......160
Market Trends.......160
Biologic Drugs Lead the Fray.......160
Biologics To Add Further Impetus to the Market.......160
1$350
   Rheumatoid Arthritis Drugs Lead the Market.......161
Enbrel and Humira Continue to Gain Share in the Anti-TNF Market.......161
Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market.......161
1$100
   Table 24: Leading Multiple Sclerosis Drugs in the US (2008): Percentage Share Breakdown of New Prescriptions Written for Avonex, Copaxone, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart).......162
Incidence of Type 1 Diabetes Mellitus Endemic in White Youth.......162
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs Market.......162
1$350
   Key Ulcerative Colitis Drugs Market in the US (2006).......163
Product Launches/Approvals.......163
7$700
   Strategic Corporate Developments.......17032$1500
   Key Players.......2027$700
   B. Market Analytics.......209
Table 25: US Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......209
1$350
   Table 26: US Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......2101$350
   Table 27: US 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......2111$350
  14. JAPAN.......2126 $950  
   A. Market Analysis.......212
Current and Future Analysis.......212
Japanese Patients Exhibit Unique Efficacy & Safety Effects.......212
Product Launches/Approvals.......212
1$100
   Strategic Corporate Developments.......2131$100
   Key Players.......2141$100
   B. Market Analytics.......215
Table 28: Japanese Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......215
1$350
   Table 29: Japanese Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......2161$350
   Table 30: Japanese 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......2171$350
  15. EUROPE.......21826 $2450  
   A. Market Analysis.......218
Current and Future Analysis.......218
Europe – A Burgeoning Market for Autoimmune Disease Therapeutics.......218
Increasing Awareness to Drive Market Growth.......218
Low Penetration to Fuel Growth in European MS DMDs Market.......218
1$100
   Table 31: Prevalence of Key Autoimmune Diseases in Europe in Millions (includes corresponding Graph/Chart).......219
Lower Treatment Rate Bodes Huge Potential for the UK MS Drug Market.......219
Drugs Hindering Disease Progression to Gain Prominence.......219
Rising Demand for Rheumatoid Arthritis Drugs in Russia.......219
1$350
   Product Launches/Approvals.......2204$400
   Strategic Corporate Developments.......22410$600
   Key Players.......2347$700
   B. Market Analytics.......241
Table 32: European Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......241
1$350
   Table 33: European Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......2421$350
   Table 34: European 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics), and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......2431$350
  16. REST OF WORLD.......24415 $1995  
   A. Market Analysis.......244
Current and Future Analysis.......244
Canada.......244
Canada – Highest Prevalence Rates for Multiple Sclerosis.......244
Sales of Biologics on the Rise in Canadian Rheumatoid Arthritis Drugs
  Market.......244
1$100
   Asia-Pacific.......245
Autoimmune Diseases Market in Asia-Pacific – An Overview.......245
Incidence of Multiple Sclerosis in India on the Rise.......245
1$100
   Overview of Rheumatoid Arthritis in Australia.......246
Table 35: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Age Group (includes corresponding Graph/Chart).......246
1$350
   Table 36: Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Sex (includes corresponding Graph/Chart).......247
Overview of Irritable Bowel Diseases in Australia.......247
1$350
   Product Launches/Approvals.......2482$200
   Strategic Corporate Developments.......2505$500
   Key Player.......2551$100
   B. Market Analytics.......256
Table 37: Rest of World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).......256
1$350
   Table 38: Rest of world Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).......2571$350
   Table 39: Rest of World 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......2581$350
COMPETITION 664$995
  
Total Companies Profiled: 138 (including Divisions/Subsidiaries - 155)

Region/Country                 Players


The United States                 83   
Canada                             6
Japan                              7
Europe                            43
     France                        2
     Germany                       8
     The United Kingdom           10
     Italy                         1
     Rest of Europe               22
Asia-Pacific (Excluding Japan)    10
Middle East                        6
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign